US Edition
AstraZeneca beats profit expectations on robust drug sales, US demand
GREATER LONDON, ENGLAND, JUL 29 – AstraZeneca reported 11% revenue growth to $14.46 billion driven by cancer drug sales and a 13% rise in U.S. revenue despite tariff and pricing challenges.
- On July 29, AstraZeneca beat second-quarter profit expectations, reporting a 27% increase in net profit and maintaining its annual outlook while lifting its interim dividend by 3%.
- Last month, analysts expected $14.15 billion in revenue, but AstraZeneca reported $14.46 billion with 11% growth, driven by oncology drug sales.
- AstraZeneca's sales grew 11% to $14.46 billion with core earnings of $2.17 per share, and the US market contributed 44% of sales, last month.
- Amid sector-wide tariff concerns, AstraZeneca plans to spend $50 billion expanding US manufacturing and research by 2030, targeting $80 billion in revenue.
- The company aims to reach $80 billion in annual revenue by 2030, targeting 20 new medicines and shifting focus from China to the US footprint.
Insights by Ground AI
Does this summary seem wrong?
17 Articles
17 Articles
AstraZeneca beats profit expectations on robust drug sales, US demand
AstraZeneca on Tuesday beat second-quarter revenue and profit expectations on robust sales of newer cancer, heart and kidney disease medicines and strong demand in the U.S., where it has invested $50 billion to expand amid tariff threats from Washington.
·United Kingdom
Read Full Article
AstraZeneca beats second-quarter profit expectations
AstraZeneca has today beaten second-quarter profit forecastson robust sales of cancer, heart and kidney disease drugs and strong demand in the US, where it has invested $50 billion to expand amid tariff threats from President Donald Trump.
·Ireland
Read Full ArticleCoverage Details
Total News Sources17
Leaning Left2Leaning Right0Center7Last UpdatedBias Distribution78% Center
Bias Distribution
- 78% of the sources are Center
78% Center
L 22%
C 78%
Factuality
To view factuality data please Upgrade to Premium
